Approaches to Treating Liver Metastases Arising from Uveal Melanoma
Overview
Uveal melanoma is the most common primary intraocular malignancy in adults, with liver metastases occurring in approximately 90% of metastatic cases. Despite effective local control of primary tumors, metastatic disease carries a poor prognosis with a median overall survival of about one year. Treatment options include systemic therapies such as tebentafusp, the only systemic agent shown to improve survival, and various liver-directed therapies including surgical resection and embolization techniques.
Background
Uveal melanoma arises from melanocytes in the uveal tract and differs genetically and clinically from cutaneous melanoma. The incidence has increased over recent decades, with half of patients developing distant metastases, predominantly in the liver. Primary tumor treatments include brachytherapy and proton beam radiotherapy, which provide good local control but do not prevent metastases. Genetic alterations such as GNAQ/GNA11 mutations and BAP1 loss are associated with metastatic risk and poor prognosis.
Data Highlights
Parameter
Value
5-year local recurrence rate after brachytherapy
10%
Median overall survival after metastases detection
~1 year
2-year survival rate with metastases
8%
Percentage of patients with liver metastases
~90%
Incidence of uveal melanoma in Northern Europe (2022)
12 per million per year
Percentage of uveal melanomas with GNAQ or GNA11 mutations
~90%
Percentage of primary tumors with BAP1 mutations
47%
Percentage of metastatic tumors with BAP1 mutations
84%
Key Findings
Uveal melanoma metastasizes predominantly to the liver in approximately 90% of metastatic cases.
Systemic therapies such as chemotherapy and immunotherapy have historically shown limited efficacy in metastatic uveal melanoma.
Tebentafusp is the first systemic treatment to demonstrate improved overall survival and is approved for patients with HLA-A*02:01 genotype.
Liver-directed therapies include surgical resection, radioembolization, chemoembolization, immune-embolization, isolated hepatic perfusion, and percutaneous hepatic perfusion.
Genetic alterations such as monosomy 3 and BAP1 mutations are strongly associated with metastatic risk and poor prognosis.
Enhanced surveillance with hepatic imaging may detect metastases earlier but has not yet improved overall survival.
Clinical Implications
Clinicians should consider genetic risk stratification to guide surveillance intensity for early detection of liver metastases. Tebentafusp offers a new systemic treatment option for eligible patients, while liver-directed therapies remain important for locoregional disease control. Combining systemic and locoregional approaches may improve outcomes and is an area of ongoing research.
Conclusion
Liver metastases from uveal melanoma present a significant clinical challenge with poor prognosis. Advances in systemic therapy with tebentafusp and evolving liver-directed treatments offer hope for improved survival in this patient population.
References
Review Article -- Approaches to Treating Liver Metastases Arising from Uveal Melanoma
